Cited by 677Colorectal Cancer Treatments and StudiesGenetic factors in colorectal cancerColorectal Cancer Surgical Treatments

The DOI matches its Crossref record; 176 of the 177 references it cites were found in a registry or an index.

From tumour heterogeneity to advances in precision treatment of colorectal cancer

Open access

Punt, Cornelis J. A., Koopman, Miriam, Vermeulen, Louis·2017·Nature Reviews Clinical Oncology

DOI 10.1038/nrclinonc.2016.171

Open this paper in CoChat — free account Open PDF

Abstract

In recent years, the high heterogeneity of colorectal cancer (CRC) has become evident. Hence, biomarkers need to be developed that enable the stratification of patients with CRC into different prognostic subgroups and in relation to response to therapies, according to the distinctive tumour biology. Currently, only RAS-mutation status is used routinely as a negative predictive marker to avoid treatment with anti-EGFR agents in patients with metastatic CRC, and mismatch-repair status can guide the use of adjuvant chemotherapy in patients with early stage colon cancer. Advances in molecular biology over the past decade have enabled a better understanding of the development of CRC, as well as the more-precise use of innovative targeted therapies for this disease, and include three fundamental achievements. First, the availability of large databases to capture and store the genomic landscape of patients with CRC, providing information on the genes that are frequently deregulated in CRC. Second, the possibility of using gene-expression profiling to differentiate the subtypes of CRC into prognostic groups. Third, results from highly sensitive next-generation sequencing analyses have led to an appreciation of the extensive intratumoural heterogeneity of CRC. Herein, we discuss these advances and place them into the clinical context, and present the novel targets and therapeutic opportunities that are on the horizon.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nrclinonc.2016.171

Cites

176 of 176 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

A genetic model for colorectal tumorigenesis
Fearon, E. R., & Vogelstein, B. (1990) · Cell · doi:10.1016/0092-8674(90)90186-i · Cited by 12,132
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
The consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170
Self-citation
A human colon cancer cell capable of initiating tumour growth in immunodeficient mice
O'Brien, C. A., Pollett, A. F., Gallinger, S., & Dick, J. E. (2006) · Nature · doi:10.1038/nature05372 · Cited by 4,174
Identification and expansion of human colon-cancer-initiating cells
Ricci‐Vitiani, L., Lombardi, D. G., Pilozzi, E., Biffoni, M., Todaro, M., Peschle, C., & Maria, R. D. (2006) · Nature · doi:10.1038/nature05384 · Cited by 4,001
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622

Show all 177 references

Sorted by citations

Items 401–500 of 677

Controlled Inflammation Drives Neutrophil‐Mediated Precision Drug Delivery in Heterogeneous Tumors
Guo, Y., Li, Y., Li, J., Cai, H., Liu, K., Duan, D., Zhang, W., Han, G., & Zhao, Y. (2025) · Advanced Science · doi:10.1002/advs.202411307 · Cited by 7
Identification of Key Genes Related With Aspartic Acid Metabolism and Corresponding Protein Expression in Human Colon Cancer With Postoperative Prognosis and the Underlying Molecular Pathways Prediction
Sun, W., Jia, C., Zhang, X., Wang, Z., Li, Y., & Fang, X. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.812271 · Cited by 6
Harnessing Minimal Residual Disease as a Predictor for Colorectal Cancer: Promising Horizons Amidst Challenges
Wen, X., Coradduzza, D., Shen, J., Scanu, A. M., Muroni, M. R., Massidda, M., Rallo, V., Carru, C., Angius, A., & Miglio, M. R. D. (2023) · Medicina · doi:10.3390/medicina59101886 · Cited by 7
“Despite chemotherapy being a common clinical approach for CRC, its actual beneﬁt is for a limited patient subset [33,34].”
Background
Stromal localization of inactive CD8+ T cells in metastatic mismatch repair deficient colorectal cancer
Küçükköse, E., Baars, M. J. D., Amini, M., Schraa, S. J., Floor, E., Bol, G. M., Rinkes, I. H. M. B., Roodhart, J. M. L., Koopman, M., Laoukili, J., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02500-x · Cited by 7
Self-citation
Label-free quantification of imaging features in the extracellular matrix of left and right-sided colon cancer tissues
Arora, B., Kulkarni, A., Markus, M. A., Ströbel, P., Bohnenberger, H., Alves, F., & Ramos‐Gomes, F. (2024) · Scientific Reports · doi:10.1038/s41598-024-58231-3 · Cited by 8
Angiogenesis in 90Y-Radioembolization of Colorectal Liver Metastases
Alsultan, A. A., Barentsz, M. W., Smits, M. L. J., Koopman, M., Lam, M. G. E. H., & Rosenbaum, C. E. N. M. (2019) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2019.01.004 · Cited by 6
Self-citation
Long-Chain Noncoding RNA PVT1 Gene Polymorphisms Are Associated with the Risk and Prognosis of Colorectal Cancer in the Han Chinese Population
Zhang, L., & Mao, J. (2019) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2019.0078 · Cited by 6
“Clinically, the primary treatments for CRC include surgery, chemotherapy, radiotherapy, and targeted therapy (Navez et al ., 2016; Punt et al ., 2017; Moridikia et al ., 2018).”
Precision Medicine for the Management of Therapy Refractory Colorectal Cancer
Taghizadeh, H., Mader, R. M., Müllauer, L., Erhart, F., Kautzky‐Willer, A., & Prager, G. W. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10040272 · Cited by 6
Identification and validation of a novel stress granules-related prognostic model in colorectal cancer
Liu, Z., Zhao, E., Li, H., Lin, D., Huang, C., Zhou, Y., Zhang, Y., Pan, X., Liao, W., & Li, F. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1105368 · Cited by 5
“A high level of molecular heterogeneity makes it possible for relapses and death risks to vary considerably even among patients with high similarities in clinical and pathological features (Weiser et al., 2011; Punt et al., 2017).”
Background
Identification of a prognostic signature in colorectal cancer using combinatorial algorithm‐driven analysis
Alnabulsi, A., Wang, T., Pang, W., Ionescu, M., Craig, S. G., Humphries, M. P., McCombe, K. D., Salto‐Tellez, M., Alnabulsi, A., & Murray, G. I. (2022) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.258 · Cited by 5
“The main obstacle to better survival rates is the molecular heterogeneity of colorectal cancer which is reflected clinically through variations in tumour progression, prognosis, and response to treatment [4].”
Background
In vitro anticancer, antioxidant, cytotoxic activity and phytochemical characterization of Inula viscosa L. essential oil against colorectal cancer cell line HCT-116
Yıldırım, B. A., Küçükaydın, S., & Kordalı, Ş. (2024) · Journal of Essential Oil Bearing Plants · doi:10.1080/0972060x.2024.2384515 · Cited by 5
Mismatch Repair Status in Patient-Derived Colorectal Cancer Organoids Does Not Affect Intrinsic Tumor Cell Sensitivity to Systemic Therapy
Küçükköse, E., Wensink, G. E., Roelse, C. M., van Schelven, S. J., Raats, D., Boj, S. F., Koopman, M., Laoukili, J., Roodhart, J. M. L., & Kranenburg, O. (2021) · Cancers · doi:10.3390/cancers13215434 · Cited by 5
“Examples are the selection of patients with mutant BRAF tumors for treatment with BRAF inhibitor combination therapies, the selection of patients with dMMR tumors for immunotherapy, and the exclusion of patients with KRAS mutant tumors from treatment with EGFR-targeting therapy [30].”
BackgroundSelf-citation
Latent class analysis-derived classification improves the cancer-specific death stratification of molecular subtyping in colorectal cancer
Zhou, W., He, M.-M., Wang, F., Xu, R., Wang, F., & Zhao, Q. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00412-w · Cited by 5
“As one of the most common cancers worldwide 1,2 , colorectal cancer (CRC) is characterized by high heterogeneity concerning clinical and biological features, resulting in diverse treatment responses and prognoses 3,4 .”
Survival of Patients with Deficient Mismatch Repair Versus Proficient Mismatch Repair Metastatic Colorectal Cancer Receiving Curative-Intent Local Treatment of Metastases in a Nationwide Cohort
Zwart, K., van der Baan, F. H., Punt, C. J. A., Wensink, G. E., Bolhuis, K., Laclé, M. M., van Grevenstein, W. M. U., Hagendoorn, J., de Hingh, I. H. J. T., Koopman, M., et al. (2023) · Annals of Surgical Oncology · doi:10.1245/s10434-023-13974-7 · Cited by 5
Self-citation
Unveiling mitophagy-mediated molecular heterogeneity and development of a risk signature model for colorectal cancer by integrated scRNA-seq and bulk RNA-seq analysis
Gao, H., Zou, Q., Ma, L., Cai, K., Sun, Y., Li, L., Ren, D., & Hu, B. (2022) · Gastroenterology report · doi:10.1093/gastro/goad066 · Cited by 5
Characterization of dabrafenib-induced drug insensitivity via cellular barcoding and collateral sensitivity to second-line therapeutics
Baygin, R. C., Yilmaz, K. C., & Acar, A. (2024) · Scientific Reports · doi:10.1038/s41598-023-50443-3 · Cited by 5
Integrated analysis of tumor-associated macrophages and M2 macrophages in CRC: unraveling molecular heterogeneity and developing a novel risk signature
Shi, L., Mao, H., & Ma, J. (2024) · BMC Medical Genomics · doi:10.1186/s12920-024-01881-z · Cited by 6
“Moreover, CRC’s diverse clinical and molecular profiles exhibit marked differences in tumor progression and therapeutic responsiveness [2].”
Background
The relationship between nutritional status and prognosis in advanced gastrointestinal cancer patients in palliative care: a prospective cohort study
Mao, T., Yorke, J., Zhang, X., Shi, Y., Wang, J., Kong, X., Lam, K. K. W., Liu, Q., Yang, F., & Ho, K. Y. (2024) · Supportive Care in Cancer · doi:10.1007/s00520-024-08884-7 · Cited by 10
Emast Frequency in Colorectal Cancer: A Meta-Analysis and Literature Review
Ranjbar, R., Esfahani, A. T., Mojarad, E. N., Olfatifar, M., Aghdaei, H. A., & Mohammadpour, S. (2020) · Biomarkers in Medicine · doi:10.2217/bmm-2020-0068 · Cited by 5
Comprehensive microRNA analysis across genome-edited colorectal cancer organoid models reveals miR-24 as a candidate regulator of cell survival
Villanueva, J., Kwong, L. N., Han, T., Martinez, S. A., Shanahan, M. T., Kanke, M., Dow, L. E., Danko, C. G., & Sethupathy, P. (2022) · BMC Genomics · doi:10.1186/s12864-022-09018-1 · Cited by 6
“Recent advances in the understanding of CRC inter-tumor heterogeneity have led to substantial improvements in the therapeutic strategies utilized to treat CRC patients [4– 6] One notable example is how tumors are screened for KRAS, NRAS, and BRAF mutations to determine eligibility for anti-EGFR monoclonal antibody tre…”
Background
ROS-Responsive PLGA-NPs for Co-Delivery of DTX and DHA for Colon Cancer Treatment
Cassano, R., Trombino, S., Curcio, F., Sole, R., Calviello, G., & Serini, S. (2024) · International Journal of Translational Medicine · doi:10.3390/ijtm4020016 · Cited by 6
“Presently, conventional (such as surgery, radiotherapy and chemotherapy) or innovative (targeted therapy and immunotherapy) anticancer therapies are applied for this kind of cancer [3,4].”
Background
Tumor enhancement of colorectal liver metastases on preoperative gadobutrol-enhanced MRI at 5 minutes post-contrast injection is associated with overall survival post-hepatectomy
Cheung, H., Karanicolas, P. J., Coburn, N. G., Law, C., & Milot, L. M. (2019) · Quantitative Imaging in Medicine and Surgery · doi:10.21037/qims.2018.10.15 · Cited by 5
“It is increasingly being understood that colorectal cancer is not a homogeneous disease and that the biology of tumors may account for a large range of differences in response to treatment (5).”
Background
Accuracy of Computed Tomography Staging of Mismatch Repair-Deficient Colon Cancer
Linhares, S. M., Srikumar, T., Shin, C., Mathur, M., AlKukhun, A. O., Mongiu, A. K., Leeds, I. L., Reddy, V. B., Pantel, H., & Cecchini, M. (2025) · JCO Oncology Practice · doi:10.1200/op-25-00505 · Cited by 5
Functional Precision Medicine Using MicroOrganoSpheres for Treatment Response Prediction in Advanced Colorectal Cancer
Gobits, R., Schleußner, N., Oliver, G. R., Schoenberg, M. R., Domingues, A. M. D. J., Ramkumar, P., Suen, S. W. F., Koomen, M., Paolucci, F., Martens, K., et al. (2026) · JCO Precision Oncology · doi:10.1200/po-25-00501 · Cited by 4
VEGF-C propagates ‘onward’ colorectal cancer metastasis from liver to lung
Poghosyan, S., Frenkel, N. C., van den Bent, L., Raats, D., Spaapen, T. O. M., Laoukili, J., Rinkes, I. H. M. B., Kranenburg, O., & Hagendoorn, J. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02892-4 · Cited by 4
“A signi ﬁ cant subgroup of patients with “ oligometastatic ” disease, however, may achieve long-term survival with extensive local and systemic therapies [3, 4].”
Molecular characterization of colorectal cancer (CRC) using next generation sequencing (NGS) in bridging the gap between research and clinical practice: from biomarker discovery to clinical implementation
Afolabi, H. A., Salleh, M. S. M., Zakaria, Z., Seng, C. E., Nafi, S. N. M., Aziz, A. A. A., Zainon, W. M. N. W., Irekeola, A. A., Wada, Y., Al-Mhanna, S. B., et al. (2025) · Discover Oncology · doi:10.1007/s12672-025-01960-2 · Cited by 4
Construction of a Risk Model for Colon Cancer Prognosis Based on Ubiquitin-Related Genes
Hu, B., Chen, Z., Yao, F., & Li, B. (2023) · The Turkish Journal of Gastroenterology · doi:10.5152/tjg.2023.22465 · Cited by 4
Loss of RAS Mutations in Liquid Biopsies of Patients With Multi-Treated Metastatic Colorectal Cancer
Albuquerque, J., da Silva, D. N., Padrão, T. G., Leal-Costa, L., Bizarro, R., Correia, J., Baptista, C., Machete, M., Prazeres, G., Margarido, I., et al. (2023) · The Oncologist · doi:10.1093/oncolo/oyad299 · Cited by 4
Advance precision medicine to combat colorectal cancer
Mujawar, S., Deshpande, A., Gherkar, A., Kolhe, S., Simon, S. E., & Prajapati, B. G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13870-6.00004-0 · Cited by 4
Metabolic subtypes and immune landscapes in esophageal squamous cell carcinoma: prognostic implications and potential for personalized therapies
Yu, X.-W., She, P., Chen, F.-S., Chen, Y.-Y., Zhou, S. Y., Wang, X., Lin, X.-R., Liu, Q., Huang, Z., & Qiu, Y. (2024) · BMC Cancer · doi:10.1186/s12885-024-11890-x · Cited by 4
“However, even cases with similar clinicopathological characteristics can exhibit significantly different risks of death and recurrence due to substantial molecular heterogeneities [7, 8].”
Background
Distinct molecular profiles drive multifaceted characteristics of colorectal cancer metastatic seeds
Zhao, Y., Zhang, B., Ma, Y., Guo, M., Zhao, F., Chen, J., Wang, B., Jin, H., Zhou, F., Guan, J., et al. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20231359 · Cited by 4
“Identifying metastatic seeds within primary CRC tumors Given the high intratumor heterogeneity of primary CRC tumors at the molecular level (Punt et al., 2017), we investigated whether SC-PDCC lines have varying degrees of metastatic potential.”
Investigation of ENO2 as a promising novel marker for the progression of colorectal cancer with microsatellite instability-high
Cai, J., Yang, Y., Zhang, L., Fang, Y., Zhang, Y., Tan, M., Zhang, J., Tang, C., Ren, H., Wang, L., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-12332-4 · Cited by 4
“Colorectal cancer (CRC) is a prevalent category of gastrointestinal malignancies with high incidence and significant heterogeneity [1].”
Background
Gene mutation profiling in microsatellite instability colorectal cancer and its association with the efficacy of immunotherapy: A retrospective study
Liu, Y., Cui, K., & Ma, W. (2024) · Cancer Medicine · doi:10.1002/cam4.6910 · Cited by 4
“3,21 The statistical analysis reveals a potentially distinct mutational landscape in MSI-H colorectal cancer compared to MSS colorectal cancer.”
Background
Identification of Six Genes as Diagnostic Markers for Colorectal Cancer Detection by Integrating Multiple Expression Profiles
Wu, P., Yang, X., Qiao, L., & Gong, Y. (2022) · Journal of Oncology · doi:10.1155/2022/3850674 · Cited by 4
An analysis of the significance of the Tre2/Bub2/CDC 16 (TBC) domain protein family 8 in colorectal cancer
Liu, Y., Li, J.-P., Li, H.-R., Zeng, S., Chen, Y., Han, M., Ye, Q., Zhou, J., Liu, S., & Zou, X. (2022) · Scientific Reports · doi:10.1038/s41598-022-15629-1 · Cited by 4
Long-term Survival Update and Extended RAS Mutational Analysis of the CAIRO2 Trial: Addition of Cetuximab to CAPOX/Bevacizumab in Metastatic Colorectal Cancer
ten Hoorn, S., Mol, L., Sommeijer, D. W., Nijman, L. E., van den Bosch, T., de Back, T. R., Ylstra, B., van Dijk, E., van Noesel, C. J. M., Reinten, R. J. A., et al. (2022) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2022.11.006 · Cited by 4
Self-citation
Effect of HtrA1 Polymorphism on Sensitivity to Chemotherapy in Patients with Colon Cancer
Yao, Y., & Li, N. (2020) · Medical Science Monitor · doi:10.12659/msm.921933 · Cited by 4
Deep learning to segment liver metastases on CT images: impact on a radiomics method to predict response to chemotherapy
Giannini, V., Defeudis, A., Rosati, S., Cappello, G., Vassallo, L., Mazzetti, S., Panić, J., Regge, D., & Balestra, G. (2020) · IEEE International Symposium on Medical Measurements and Applications (MeMeA) · doi:10.1109/memea49120.2020.9137150 · Cited by 4
“The high heterogeneity that characterizes CRC can lead to differences in response to treatment, either between the primary tumor and the metastatic lesions or among different metastatic lesions in the same patient [2].”
Background
Identification of a metabolic signature to predict overall survival for colorectal cancer
Yuan, Y., Liu, M., Hou, P., Liang, L., Sun, X., Gan, L., & Liu, T. (2021) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2021.1948605 · Cited by 4
Identification of progression related LncRNAs in colorectal cancer aggressiveness
Wei, X., Sun, X., Wang, M., Wang, X., Li, K., Jiang, R., Jia, X., & Wang, W. (2025) · Scientific Reports · doi:10.1038/s41598-025-02096-7 · Cited by 4
Pharmacological interventions targeting β-adrenoceptors in colorectal cancer: an evolving paradigm
Ghosn, A., Bassam, K., Zein, M. A., Nasser, S. A., Pintus, G., & Eid, A. H. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01925-5 · Cited by 3
“CRC itself represents a highly heterogenous disease characterized by diverse tumor biology, a spectrum of genetic and epigenetic alterations, and patient-specific risk factors such as environmental exposures, microbiome composition and metabolic status (Punt et al. 2017).”
Integrated Multi‐Omics Profiling to Characterize Molecular Subtypes and Reveal Potential Therapeutic Strategies for Colorectal Cancer
Guo, X., Tian, S., Li, X., Zhang, H., Wang, A., Jin, Y., Bian, C., Lin, J., Liu, S., Tang, M., et al. (2025) · MedComm · doi:10.1002/mco2.70492 · Cited by 4
The Future of Nanomedicine
Shi, Y., Chen, L., Zhu, M., & Zhao, Y. (2023) · Micro/Nano technologies · doi:10.1007/978-981-16-8984-0_24 · Cited by 4
Ubiquitination-related Gene UBTD1 Mediates Poor Prognosis of Colorectal Cancer and Affects Colorectal Cancer Cell Proliferation and Ferroptosis
Jin, Y., Liao, L., Guo, L., Chen, Q., Tang, B., Jiang, J., Zhu, J. Y., & Bai, M. (2025) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/0115748928323408241002131753 · Cited by 3
Mutation SVCT2 promotes cell proliferation, invasion and migration in colorectal cancer
Park, S. S., Ryu, Y. S., Koh, D., Hong, S., Moon, J.-H., Shin, J.-S., Kim, M. J., Kim, D. Y., Hong, J. K., Kim, E. H., et al. (2021) · Journal of Cancer · doi:10.7150/jca.57463 · Cited by 3
“CRC is a genetically heterogeneous disease involving a vast array of mutations, suggesting that targeted therapy, for specific molecular aberrations, is likely to be effective for patients [8].”
Background
The Future of Nanomedicine
Shi, Y., Chen, L., Zhu, M., & Zhao, Y. (2022) · Micro/Nano technologies · doi:10.1007/978-981-13-9374-7_24-1 · Cited by 3
In silico development and in vitro validation of a novel five-gene signature for prognostic prediction in colon cancer.
Zhu, Q., Rao, B., Chen, Y., Jia, P., Wang, X., Zhang, B., Wang, L., Zhao, W., Hu, C., Tang, M., et al. (2023) · PubMed Central · Cited by 3
ROR1-AS1: A Meaningful Long Noncoding RNA in Oncogenesis
Fan, H. Z., Zhou, Y., Zhang, Z., Zhou, G., & Yuan, C. (2024) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/0113895575294482240530154620 · Cited by 3
GTF2H5 Identified as a crucial synthetic lethal target to counteract chemoresistance in colorectal cancer
Nie, J., Liu, X., Xu, M., Chen, X., Hu, S., Gu, X., Sun, H., Gao, T., Pan, Y., & Wang, S. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.102097 · Cited by 3
Polymorphisms in the ICOS/CD28-ICOSL pathway are related to capecitabine-based chemotherapy response in advanced colon cancer patients
Mao, Y., Wang, C., Meng, F., Kong, J., Cao, S.-P., Jiang, Y., Wang, W., & Hua, D. (2018) · Molecular Immunology · doi:10.1016/j.molimm.2018.02.017 · Cited by 3
A Robust Prognostic Signature of Tumor Microenvironment in Colorectal Cancer
Liu, J., Yu, F., Liu, Z., Wang, X., & Li, J. (2021) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2021.0171 · Cited by 3
Choosing the right strategy based on individualized treatment effect predictions: combination versus sequential chemotherapy in patients with metastatic colorectal cancer
Kwakman, J. J. M., van Kruijsdijk, R. C. M., Elias, S. G., Seymour, M., Meade, A. M., Visseren, F. L. J., Punt, C. J. A., & Koopman, M. (2019) · Acta Oncologica · doi:10.1080/0284186x.2018.1564840 · Cited by 3
“Randomized phase III trials in mCRC generally represent a heterogeneous study population, which is evidenced by a large amount of clinical and molecular prognostic parameters that have been identified in recent years [20].”
BackgroundSelf-citation
RETRACTED: Eco-friendly oriented synthesis of CeO2 NPs corroborated over silica gel: Synthesis, description of distinctive features and the study of its antioxidant and anti-human colorectal cancer action
Huan, G. (2024) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2024.140172 · Cited by 2
Retracted
Prognostic importance of splicing-triggered aberrations of protein complex interfaces in cancer
Newaz, K., Schaefers, C., Weisel, K. C., Baumbach, J., & Frishman, D. (2024) · NAR Genomics and Bioinformatics · doi:10.1093/nargab/lqae133 · Cited by 2
“The other BioCRPE is between exons with Ensembl IDs ‘ENSE00003554215’ and ‘ENSE00001303150’ from proteins Q9BRT9 and Q9Y248, respectively.”
BackgroundInfluential
ATM is associated with the prognosis of colorectal cancer: a systematic review
Wu, P., & Wen, Z. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1470939 · Cited by 2
“CRC is a highly heterogeneous disease with respect to its clinical and biological features, resulting in striking differences in disease progression and treatment response among patients (19).”
Patient-derived colorectal microtumors predict response to anti-PD-1 therapy
Nguyen, D., Schaller, M. A., Terracina, K. P., Xu, X., Pedro, D. I., Pepe, A., Urueña, J. M., Dupee, Z., Diodati, N. G., Smolchek, R. A., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1640500 · Cited by 2
CF10 Displayed Improved Activity Relative to 5-FU in a Mouse CRLM Model Under Conditions of Physiological Folate
Okechukwu, C. C., Ma, X., Li, W., D’Agostino, R., Rees, M. G., Ronan, M. M., Roth, J. A., & Gmeiner, W. H. (2025) · Cancers · doi:10.3390/cancers17172739 · Cited by 2
“Further, CF10 was highly potent regardless of MSI/MSS status or KRAS mutation status, consistent with its broad use for CRC treatment regardless of the factors used to stratify CRC patients for 5-FU-based chemotherapy [28].”
Hematological markers as prognostic predictors in patients undergoing colon cancer surgery
Stuva, J. P. G., Pérez-López, C., Romero, M. S. R., García, A. B., Vivas, P., Ripoll, D., & Gordo, S. L. (2025) · Scientific Reports · doi:10.1038/s41598-025-33554-x · Cited by 3
“The majority of CRC develops from de adenoma-carcinoma sequence 8,13 .”
Intratumor heterogeneity score reveals immune landscape and survival stratification in colorectal cancer
Wang, Z., Ma, L., Cao, J., Chen, X., Chang, X., Ma, R., Lv, H., Zhang, Z., Li, H., & Jiang, T. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1671148 · Cited by 2
Multi-omics driven immune classification of colorectal cancer: Implications for immunotherapy efficacy prediction and enhancement with WNT signaling inhibition
Hu, C., Cai, D., You, W., Zhou, Z., Liu, J., Li, C., Lv, M., Gai, B., Chen, C., Huang, X., et al. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218425 · Cited by 2
Targeting the tumor microenvironment for sensitization of colorectal cancer to chemotherapy and radiotherapy
Wu, J., & Zhang, L. (2026) · Pathology - Research and Practice · doi:10.1016/j.prp.2026.156480 · Cited by 2
Preoperative HALP and LMR predict disease-free survival in stage III colon cancer and enable nomogram-based risk stratification
Xu, J., Qu, F., Wang, X., Liang, S., Jiang, D., & Wang, Z. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1825101 · Cited by 2
“This variability highlights the need for additional biomarkers that re ﬂ ect host – tumor interactions beyond conventional anatomical classi ﬁ cation (6, 7).”
Exploring the prognostic function of TMB-related prognostic signature in patients with colon cancer
Zhao, Y., Liang, X., Duan, X., & Zhang, C. (2023) · BMC Medical Genomics · doi:10.1186/s12920-023-01555-2 · Cited by 2
“COAD is a tumor with high heterogeneity, which resulted from a series of genetic mutation in tumor cells [3, 4].”
Background
Intratumor heterogeneity in colorectal cancer: Distribution of tumor suppressor gene variants with regard to patient lymph node status
Wątor, G., Seweryn, M. T., Kapusta, P., Świrta, J. S., Walega, P. J., Barczyński, M., & Wołkow, P. P. (2023) · Clinical Genetics · doi:10.1111/cge.14388 · Cited by 2
“Despite this huge knowledge collected by the TCGA initiative, currently only DNA mismatch-repair status, RAS mutation, and possibly BRAF mutation status influence clinical decision-making.(25) We postulate that an explanation of how the tumor has evolved and which genetic biomarker is the most important one for diagno…”
Background
Modulators of the Nrf2 Signaling Pathway Enhance the Cytotoxic Effect of Standard Chemotherapeutic Drugs on Organoids of Metastatic Colorectal Cancer
Razumovskaya, A. V., Silkina, M. O., Nikulin, S. V., Tonevitsky, A., & Alekseev, B. Y. (2024) · Bulletin of Experimental Biology and Medicine · doi:10.1007/s10517-024-06093-0 · Cited by 2
Pokemon inhibits Bim transcription to promote the proliferation, anti-anoikis, invasion, histological grade, and dukes stage of colorectal neoplasms
Wang, Y., Zeng, H., Li, L., Liu, J., Lin, J., Bie, Y., Wang, S., Cheng, X., Nashun, B., Yao, Y., et al. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05904-1 · Cited by 2
“The primary cause of mortality in CRC is early, undetected, and uncontrolled metastasis (Punt et al. 2017; Sa et al. 2018).”
Background
Hyaluronic acid regulated facile synthesis of size-tunable multifunctional nanomedicine for effective cancer therapy
Dai, X., Yin, Y., Wang, C., & Xu, H. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.138668 · Cited by 2
Identifying TP53RK as a key regulator of colorectal cancer survival and a potential therapeutic target
Choi, Y. H., Park, S., Yang, S.-J., Kim, E., Cho, Y., Yang, H.-J., Yi, E. C., Song, S., & Kim, T. (2025) · Scientific Reports · doi:10.1038/s41598-025-21082-7 · Cited by 2
Comparative Study of NGS Platform Ion Torrent Personal Genome Machine and Therascreen Rotor-Gene Q for the Detection of Somatic Variants in Cancer
Lombardi, A., Russo, M., Luce, A., Morgillo, F., Tirino, V., Misso, G., Martinelli, E., Troiani, T., Desiderio, V., Papaccio, G., et al. (2020) · Microarrays · doi:10.3390/ht9010004 · Cited by 2
In silico identification of the specific pathways in each stage of colorectal cancer and the association of their top genes with drug resistance and sensitivity
Hashemi, R., Peymani, M., Ghaedi, K., & Saffar, H. (2022) · Medical Oncology · doi:10.1007/s12032-022-01661-8 · Cited by 2
“One of the most important challenges can be the heterogeneity, which may affect the process of gene expression change, resistance to chemotherapy drugs, and prognosis [2].”
Background
Low KISS 1 expression predicts poor prognosis for patients with colorectal cancer: A meta‐analysis
Wang, X., Fang, P., Zhang, C., Xu, Y., Song, X., Liang, J., & Xia, Q. (2019) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13093 · Cited by 2
Fiber-associated Lachnospiraceae reduce colon tumorigenesis by modulation of the tumor-immune microenvironmentPreprint
Almeida, A. S., Tran, T. T. T., Ghosh, T. S., Ribière, C., Foley, C., Azevedo, L. A., Pellanda, P., Frei, W., Hueston, C. M., Kumar, R. S., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.24.432654 · Cited by 2
Single-cell RNA sequencing reveals microenvironment context-specific routes for epithelial-mesenchymal transition in pancreas cancer cellsPreprint
Brown, B. A., & Lazzara, M. J. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.30.542969 · Cited by 2
“One of the ways to combat this across carcinomas could be molecular subtyping to identify patients that will likely be more responsive (51).”
Background
Editorial: The impact of genetics on CRC therapy: from adaptive mutability to drug resistance
Crisafulli, G., & Siravegna, G. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1260158 · Cited by 2
“In the era of precision oncology, the accurate stratification of patients based on their tumor’s genetic features is crucial to guide effective therapeutic interventions (5).”
Background
Molecular Oncology in Management of Colorectal Cancer
Vemala, R. N. G., Katti, S. V., Sirohi, B., Manikandan, D., & Nandakumar, G. (2021) · Indian Journal of Surgical Oncology · doi:10.1007/s13193-021-01289-6 · Cited by 2
“The vulnerabilities with targeted therapy in metastatic colorectal cancers have created a necessity to identify biomarkers that aid in predicting likely sensitivity and resistance prior to initiating any therapy [78, 86].”
Background
Cellular Ligand–Receptor Perturbations Unravel MEIS2 as a Key Factor for the Aggressive Progression and Prognosis in Stage II/III Colorectal Cancer
Xu, H., Chen, S., Li, J., Weng, S., Ren, Y., Zhang, Y., Wang, L., Liu, L., Guo, C., Xing, Z., et al. (2023) · Journal of Proteome Research · doi:10.1021/acs.jproteome.3c00626 · Cited by 1
Prediction of postoperative disease-free survival in colorectal cancer patients using CT radiomics nomogram: a multicenter study
Xu, G.-D., Feng, F., Cui, Y.-F., Fu, Y.-G., Xiao, Y., Chen, W., & Li, M.-M. (2025) · Acta Radiologica · doi:10.1177/02841851241302521 · Cited by 2
“However, owing to the marked heterogeneity of tumors, considerable disparities in prognoses exist among patients with the same pathological stage (5,6).”
BRAFV600E augments WNT signaling in colorectal cancer via aberrant DNA methylation
Bouazzaoui, L. E., Bugter, J. M., Küçükköse, E., Verheem, A., Post, J. B., Fenderico, N., Rinkes, I. H. M. B., Snippert, H. J. G., Maurice, M. M., & Kranenburg, O. (2025) · iScience · doi:10.1016/j.isci.2025.112708 · Cited by 4
Adaptive immune responses associated with the progression of premalignant lesions to colorectal cancer
Chen, Z., Kim, D., Wang, J., Huang, Q., Gao, Y., Zheng, J., Lyu, L., Li, Y., Lu, L., Xie, R., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-17653-3 · Cited by 1
HUWE1 loss promotes stemness and drug resistance in CRC with dysregulated β-catenin destruction complex
Lee, C., Park, S., Han, I., & Yoon, S. K. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02731-2 · Cited by 1
“Despite the diversi ﬁ cation and advancements in cancer treatments leading to improved clinical outcomes for CRC patients, the prognosis remains poor due to the high heterogeneity and complexity of CRC [2, 3].”
Review Article: β-Catenin-Driven Cancer Stemness in Colorectal Cancer: Molecular Targets and Therapeutic Opportunities
Okotel, M., & Huang, C. (2025) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2025060830 · Cited by 1
Pyrotinib Plus Trastuzumab as an Effective Later-Line Therapeutic Strategy for HER2-Positive Metastatic Colorectal Cancer: Results from a Phase II Study
Yang, W., Zhang, J., Wu, G., Zhang, W., Zhou, A., Yang, L., & Sun, Y. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s558378 · Cited by 2
Loss of SATB2 in colorectal cancer is associated with inferior survival and adverse clinicopathologic features: a meta-analysis
Maguire, B., Prehn, J. H. M., & Burke, J. P. (2025) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqaf124 · Cited by 1
Prediction of immunotherapeutic responses by a classifier model based on inflammation-associated tumor microenvironment signatures in colorectal cancer
Gong, Z., Feng, Y., & Tu, J. (2026) · Discover Oncology · doi:10.1007/s12672-026-04548-6 · Cited by 1
Dysregulated immune microenvironment in metastatic colorectal cancer
An, S., Yu, Z., Li, J., & Wei, M. (2026) · Medical Oncology · doi:10.1007/s12032-025-03112-6 · Cited by 1
“(CUP) have recently been delineated, most notably a CRC-like CUP subtype [ 4].”
Clonal evolution and mutational trajectories of metastatic colorectal cancer shaped by anticancer therapies
Lee, W. H., Kim, B., Nam, C. H., Yeo, H. Y., Lee, D. W., Park, S.-J., Oh, J. H., Han, S., Lim, M. C., Kim, H., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-74384-3 · Cited by 2
“First, the relatively small number of patients limits the generalizability of our ﬁ ndings, given the inter-patient heterogeneity in CRC 78 .”
Progress in the March to Precision Cancer Medicine
Nakakura, E. K. (2017) · JAMA Surgery · doi:10.1001/jamasurg.2017.3895 · Cited by 1
Targeting the Tumor in Colorectal Cancer – Where do we Stand with Precision Medicine in 2020
Siebenhüner, A. R. (2020) · healthbook TIMES Oncology Hematology · doi:10.36000/hbt.oh.2020.05.017 · Cited by 1
Deep learning-extracted CT imaging phenotypes predict response to total resection in colorectal cancer
Pan, X., Cong, H., Wang, X., Zhang, H., Ge, Y., & Hu, S. (2023) · Acta Radiologica · doi:10.1177/02841851231152685 · Cited by 1
“CRC is a heterogeneous and molecularly complex disease (24).”
Background
Integrative Multi-Omics Analysis Identifies Transmembrane p24 Trafficking Protein 1 (TMED1) as a Potential Prognostic Marker in Colorectal Cancer
Guo, X., Zhou, W., Jin, J., Lin, J., Zhang, W., Zhang, L., & Luan, X. (2024) · Biology · doi:10.3390/biology13020083 · Cited by 1
“In addition, the targeted therapy of CRC patients is still unsatisfactory due to the high tumor heterogeneity, late-stage diagnosis, and drug resistance [8–10].”
Background
DESIGN OF JACKFRUIT GUM-BASED GENIPIN CROSSLINKED NANOPARTICLES FOR SUSTAINED RELEASE OF CURCUMIN: OPTIMIZATION AND IN VITRO CHARACTERIZATION
THAKARE, S., & Gorle, A. P. (2024) · Cellulose Chemistry and Technology · doi:10.35812/cellulosechemtechnol.2024.58.07 · Cited by 1
The Impact of Blood Sample Processing on Ribonucleic Acid (RNA) Sequencing
Liu, Z., Ouyang, T., Yang, Y., Sheng, Y., Shi, H., Liu, Q., Bai, Y., & Ge, Q. (2024) · Genes · doi:10.3390/genes15040502 · Cited by 2
DESIGN AND DEVELOPMENT OF CURCUMIN LOADED CHIA SEED MUCILAGE BASED ELECTROSPRAYED NANOPARTICLES: IN VITRO-EX VIVO CHARACTERIZATION
THAKARE, S., & Gorle, A. P. (2024) · Cellulose Chemistry and Technology · doi:10.35812/cellulosechemtechnol.2024.58.23 · Cited by 1
The expression and clinical significance of CFAP65 in colon cancer
Li, Y., Ran, D., Basnet, S., Zhang, B., Pei, H., Dan, C., Zhang, Z., Zhang, L., Lu, T., Peng, Y., et al. (2024) · BMC Gastroenterology · doi:10.1186/s12876-024-03317-5 · Cited by 1
A large population-based and validated study on the follow-up management and supportive strategy of locally advanced rectal cancer patients
Yu, Y., Wu, H., Liang, H., Qiu, J., Wu, S., Shao, L., Lin, C., Wang, Z., & Wu, J. (2024) · Supportive Care in Cancer · doi:10.1007/s00520-024-08860-1 · Cited by 1
“Although there has been progress in comprehending the intricate nature of RC [14, 15], and treatment has become more tailored to individual biological characteristics [16, 17], the development of liver metastasis and lung metastasis continues to result in poor survival rates.”
The Role of Gut Microbiota in Tumor Recurrence and Therapy Resistance in Colorectal Cancer: Molecular Mechanisms and Clinical Implications
do Rêgo, A. C. M., & Araújo-Filho, I. (2025) · Japan Journal of Research · doi:10.33425/2690-8077.1173 · Cited by 1
Utility of comprehensive genomic profiling combined with machine learning for prognostic stratification in stage II/III colorectal cancer after adjuvant chemotherapy
Kobayashi, Y., Suzuki, Y., Seishima, R., Chikaishi, Y., Matsuoka, H., Nakamura, K., Shigeta, K., Okabayashi, K., Hiro, J., Otsuka, K., et al. (2025) · International Journal of Clinical Oncology · doi:10.1007/s10147-025-02722-4 · Cited by 1
“In particular, genetic analysis reveals specific molecular alterations that drive tumor behavior, whereas artificial intelligence (AI) analyzes vast datasets to determine subtle patterns and predictive markers [7–11].”
Surgery, Perioperative Treatment and Prognostic Factors Based on Genetic and Epigenetic Alterations in Colorectal Cancer
Sugimoto, K., & Sakamoto, K. (2019) · Juntendō Igaku/Juntendo igaku · doi:10.14789/jmj.2019.65.jmj19-ln02 · Cited by 1
Molekulare Tumordiagnostik – aktuelle Methoden, Anwendungsbeispiele und Ausblick
Sobottka, B., & Weber, A. (2020) · Der Onkologe · doi:10.1007/s00761-020-00748-z · Cited by 1
Molekulare Tumordiagnostik – aktuelle Methoden, Anwendungsbeispiele und Ausblick
Sobottka, B., & Weber, A. (2020) · Der Pathologe · doi:10.1007/s00292-020-00793-w · Cited by 1

Authors: Punt, C. J. A., Koopman, M., & Vermeulen, L.
Affiliations: Amsterdam UMC Location University of Amsterdam (NL)
University Medical Center Utrecht (NL)
Corresponding author: Punt, Cornelis J. A.
ORCID: Punt, Cornelis J. A.
Koopman, Miriam
Vermeulen, Louis
Venue: Nature Reviews Clinical Oncology
Publisher: Springer Science and Business Media LLC
Published: 2016-12-06
Volume: 14
Issue: 4
Pages: 235-246
ISSN: 1759-4774 (ISSN-L)
1759-4782
DOI: 10.1038/nrclinonc.2016.171
OpenAlex: W2560375214
Cited by: 654
References: 177
Citations by year: 2026: 38 · 2025: 41 · 2024: 87 · 2023: 79 · 2022: 88 · 2021: 96 · 2020: 83 · 2019: 57 · 2018: 56 · 2017: 28
FWCI: 4.73
Type: journal article
Language: en
Open access: green
pure.amsterdamumc.nl
Licence: other-oa
www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature Reviews Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Pure Amsterdam UMC (submittedVersion, other-oa)
Data Archiving and Networked Services (DANS) (submittedVersion)
Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
Utrecht University Repository (Utrecht University) (submittedVersion)
Funders: Nederlandse Organisatie voor Wetenschappelijk Onderzoek
Maag Lever Darm Stichting (MLDS-CDG 14-03)
H2020 European Research Council (638193)
Topics: Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
Keywords: colorectal cancer, intratumoral heterogeneity, precision medicine, targeted therapy, gene expression profiling, tumor subtypes, prognostic factors, predictive biomarkers, RAS mutations, DNA mismatch repair, anti-EGFR therapy, adjuvant chemotherapy, next-generation sequencing
MeSH terms: Antineoplastic Combined Chemotherapy Protocols, Forecasting, Humans, Immunotherapy, Neoplasm Metastasis, Neoplasm Proteins, Neoplasm Staging, Prognosis, Quality of Health Care, Colorectal Neoplasms, Treatment Outcome, Genetic Heterogeneity, Therapies, Investigational, Proto-Oncogene Proteins B-raf, DNA Mismatch Repair, Early Detection of Cancer, Precision Medicine, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

From tumour heterogeneity to advances in precision treatment of colorectal cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks